Login to Your Account

Salix Stock Slammed on Word of CRL for Xifaxan

By Marie Powers

Friday, February 25, 2011
Salix Pharmaceuticals Ltd. delivered bad news to investors Thursday morning. Based on a phone call with the FDA Wednesday evening, the Raleigh, N.C.-based company now expects to receive a complete response letter (CRL) on its supplemental new drug application (sNDA) for Xifaxan (rifaximin) 550-mg tablets for the treatment of non-constipation irritable bowel syndrome (non-CIBS) and IBS-related bloating.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription